853 results on '"Varga, Andrea"'
Search Results
2. The Circle of Willis Status Influences Neurological Complications of Carotid Endarterectomy with Contralateral Carotid Occlusion
3. Large-volume Permian felsic volcanism in the Tisza Mega-unit (East-Central Europe): Evidence from mineralogy, petrology, geochemistry, and geochronology
4. “Empowering Us”: A community-led survey of real-world perspectives of adults with type 1 diabetes using insulin pumps and continuous glucose monitoring to manage their glucose levels
5. Microstructural alterations measured by diffusion tensor imaging following transcatheter aortic valve replacement and their association with cerebral ischemic injury and cognitive function — a prospective study
6. Phase 1 Dose Escalation Study of the Allosteric AKT Inhibitor BAY 1125976 in Advanced Solid Cancer-Lack of Association between Activating AKT Mutation and AKT Inhibition-Derived Efficacy.
7. Reservoir heterogeneity of an Eocene mixed siliciclastic-carbonate succession, northern Pannonian Basin
8. Contralateral Carotid Occlusion With Insufficient Circle of Willis is Associated With a Higher Incidence of Neurologic Events During Carotid Endarterectomy Without Shunting
9. Selective Shunting in Carotid Endarterectomy Based on Circle of Willis Assessment Reduced Perioperative Neurologic Event and Stroke Rates
10. Pembrolizumab for the Treatment of Advanced Salivary Gland Carcinoma
11. Gefitinib plus tremelimumab combination in refractory non-small cell lung cancer patients harbouring EGFR mutations: The GEFTREM phase I trial
12. The effect of systemic factors on retinal blood flow in patients with carotid stenosis: an optical coherence tomography angiography study
13. Imaging retinal microvascular manifestations of carotid artery disease in older adults: from diagnosis of ocular complications to understanding microvascular contributions to cognitive impairment
14. Effect of Morphological Changes due Conductivity Enhancing Post Treatment on the Absorption and Photoluminescence of AgNW Thin Films
15. Onapristone Extended Release: Safety Evaluation from Phase I–II Studies with an Emphasis on Hepatotoxicity
16. Selective AKT kinase inhibitor capivasertib in combination with fulvestrant in PTEN-mutant ER-positive metastatic breast cancer
17. Implementing the European Society for Medical Oncology Scale for Clinical Actionability of Molecular Targets in a Comprehensive Profiling Program: Impact on Precision Medicine Oncology
18. Introduction
19. Witnesses and Guarantors
20. The fully synthetic glycopeptide MAG-Tn3 therapeutic vaccine induces tumor-specific cytotoxic antibodies in breast cancer patients
21. Permian felsic volcanic rocks in the Pannonian Basin (Hungary): new petrographic, geochemical, and geochronological results
22. RAF-1 (C-RAF)
23. Pembrolizumab in patients with programmed death ligand 1–positive advanced ovarian cancer: Analysis of KEYNOTE-028
24. Exploiting domain knowledge for cross-domain text classification in heterogeneous data sources
25. Pervasive early diagenetic dolomitization, subsequent hydrothermal alteration, and late stage hydrocarbon accumulation in a Middle Triassic carbonate sequence (Szeged Basin, SE Hungary)
26. Incomplete circle of Willis is associated with a higher incidence of neurologic events during carotid eversion endarterectomy without shunting
27. Effects of Metasomatism on Granite-Related Mineral Systems: A Boron-Rich Open Greisen System in the Highiş Granitoids (Apuseni Mountains, Romania)
28. Outcomes of long-term responders to anti-programmed death 1 and anti-programmed death ligand 1 when being rechallenged with the same anti-programmed death 1 and anti-programmed death ligand 1 at progression
29. Human epidermal receptor family inhibitors in patients with ERBB3 mutated cancers: Entering the back door
30. Are phase I trials safe for older patients?
31. Phase I dose-escalation study of F14512, a polyamine-vectorized topoisomerase II inhibitor, in patients with platinum-refractory or resistant ovarian cancer
32. Provenance and Variscan low-grade regional metamorphism recorded in slates from the basement of the (SW Hungary)
33. A phase I study of the HDM2 antagonist SAR405838 combined with the MEK inhibitor pimasertib in patients with advanced solid tumours
34. Prospective validation of a prognostic score for patients in immunotherapy phase I trials: The Gustave Roussy Immune Score (GRIm-Score)
35. Supplementary Table S4 from Genomic Instability and Protumoral Inflammation Are Associated with Primary Resistance to Anti–PD-1 + Antiangiogenesis in Malignant Pleural Mesothelioma
36. Supplementary Figure S5 from Genomic Instability and Protumoral Inflammation Are Associated with Primary Resistance to Anti–PD-1 + Antiangiogenesis in Malignant Pleural Mesothelioma
37. Data from Genomic Instability and Protumoral Inflammation Are Associated with Primary Resistance to Anti–PD-1 + Antiangiogenesis in Malignant Pleural Mesothelioma
38. Supplementary Methods from High-Throughput Genomics and Clinical Outcome in Hard-to-Treat Advanced Cancers: Results of the MOSCATO 01 Trial
39. Data from High-Throughput Genomics and Clinical Outcome in Hard-to-Treat Advanced Cancers: Results of the MOSCATO 01 Trial
40. Supplementary Figure Legends from High-Throughput Genomics and Clinical Outcome in Hard-to-Treat Advanced Cancers: Results of the MOSCATO 01 Trial
41. Supplementary Figure 1 from High-Throughput Genomics and Clinical Outcome in Hard-to-Treat Advanced Cancers: Results of the MOSCATO 01 Trial
42. Supplementary Figure 2 from High-Throughput Genomics and Clinical Outcome in Hard-to-Treat Advanced Cancers: Results of the MOSCATO 01 Trial
43. Safety, tolerability and antitumour activity of LY2780301 (p70S6K/AKT inhibitor) in combination with gemcitabine in molecularly selected patients with advanced or metastatic cancer: a phase IB dose escalation study
44. Phase I open-label study of afatinib plus vinorelbine in patients with solid tumours overexpressing EGFR and/or HER2
45. Supplementary Data from Long-Term Survival in Patients Responding to Anti–PD-1/PD-L1 Therapy and Disease Outcome upon Treatment Discontinuation
46. Supplementary Figure 2 from A First-in-Human Phase I Study to Evaluate the ERK1/2 Inhibitor GDC-0994 in Patients with Advanced Solid Tumors
47. Supplementary Tables 1 - 2, Figure 1 from A Dose-Escalation Study of SAR3419, an Anti-CD19 Antibody Maytansinoid Conjugate, Administered by Intravenous Infusion Once Weekly in Patients with Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
48. Supplementary Methods, Supplementary References, Supplementary Figure 1, Supplementary Tables 1-3 from First-in-Human Phase I Study of Single-agent Vanucizumab, A First-in-Class Bispecific Anti-Angiopoietin-2/Anti-VEGF-A Antibody, in Adult Patients with Advanced Solid Tumors
49. Supplementary Figure 1 from A First-in-Human Phase I Study to Evaluate the ERK1/2 Inhibitor GDC-0994 in Patients with Advanced Solid Tumors
50. Supplementary Data from A First-in-Human Phase I Study to Evaluate the ERK1/2 Inhibitor GDC-0994 in Patients with Advanced Solid Tumors
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.